Literature DB >> 11143524

[Role of radiotherapy in the treatment of multiple myeloma].

S Mose1, D Pfitzner, A Rahn, C Nierhoff, M Schiemann, H D Böttcher.   

Abstract

BACKGROUND: Chemotherapy is the treatment of choice in multiple myeloma; but there are no curative options. Therefore, the treatment rationale is characterized by reduction of symptoms and inhibition of complications. Regarding reduction of pain, treatment of (impending) fractures, and spinal cord compression radiation is an important part of palliative treatment. In our retrospective study we report the effect of radiotherapy on reduction of pain, recalcification and the reduction of neurological symptoms and evaluate factors which have an impact on therapeutic outcome. PATIENTS AND METHODS: From 1, Jan 1988 to 31, Dec 1998, 42 patients (19 women, 23 men; range of ages 46 to 85 years, median age 64.9 years) with 71 target volumes were irradiated (median dose 36 Gy, 2 to 3 Gy 5 times/week) because of symptomatic disease (67/71: osseous pain, 45/71: fractures/impending fractures, 13/71: spinal cord compression) (Tables 1 and 2). The median time from diagnosis to the first course of radiotherapy was 11.9 months (0.3 to 90 months). At the time of first irradiation, 5 and 37 patients were in tumor Stage II and III (Salmon/Durie), respectively. The median value of the Karnofsky performance was 70% (40 to 90%).
RESULTS: During follow-up (at least 6 months) in 85% of target volumes complete and partial pain relief (measured by patients' perception and the use of analgetic medication) was achieved; recurrences were seen in 8.8%. In 26/56 (46.4%) lesions evaluable a recalcification was seen whereas 17.9% showed progressive disease (comparison of radiographs before and after radiation). In 22.3% of all lesions initially with impending fracture (4/18) radiotherapy failed because of fracture after treatment (Tables 3 and 4). Simultaneous chemotherapy and a Karnofsky performance > or = 70 had a significant impact on a positive response to treatment, respectively. Spinal cord compression symptoms were reduced in 7/13 (53.8%) of patients (scaled due to the classification by Findlay 1987). The median survival from diagnosis for the entire group was 34.9 months (7.5 to 119.3 months), after irradiation 13.1 months (0.2 to 105.3 months) (Figure 1).
CONCLUSION: When adequately indicated radiotherapy has shown to be an effective palliative treatment. Taking under consideration that the results are retrospective we suppose that in multiple myeloma the local response to radiation is supported by a favorable performance status and simultaneous chemotherapy. Irradiation treatment does not change prognosis regarding overall survival.

Entities:  

Mesh:

Year:  2000        PMID: 11143524     DOI: 10.1007/pl00002317

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  7 in total

1.  [Radiotherapy for solitary plasmacytoma and multiple myeloma].

Authors:  M C Schmaus; D Neuhof
Journal:  Radiologe       Date:  2014-06       Impact factor: 0.635

2.  Effects of zoledronate on the radiation-induced collagen breakdown: a prospective randomized clinical trial.

Authors:  M Gierloff; M Reutemann; A Gülses; P Niehoff; J Wiltfang; Y Açil
Journal:  Clin Transl Oncol       Date:  2014-11-26       Impact factor: 3.405

3.  Impact of radiotherapy on pain relief and recalcification in plasma cell neoplasms: long-term experience.

Authors:  Mario Balducci; Silvia Chiesa; Stefania Manfrida; Elena Rossi; Tommaso Za; Vincenzo Frascino; Berardino De Bari; Stefan Hohaus; Francesco Cellini; Giovanna Mantini; Giuseppe Roberto D'Agostino; Maria Antonietta Gambacorta; Antonello Leone; Vincenzo Valentini; Valerio De Stefano
Journal:  Strahlenther Onkol       Date:  2011-01-24       Impact factor: 3.621

Review 4.  [Benefits of radiotherapy for patients with solitary plasmacytoma or multiple myeloma].

Authors:  Laila König; Klaus Herfarth
Journal:  Radiologe       Date:  2021-11-11       Impact factor: 0.635

5.  Effects of Radiotherapy in the treatment of multiple myeloma: a retrospective analysis of a Single Institution.

Authors:  Christiane Matuschek; Thomas A Ochtrop; Edwin Bölke; Ute Ganswindt; Roland Fenk; Stephan Gripp; Patric Kröpil; Peter Arne Gerber; Kai Kammers; Jackson Hamilton; Klaus Orth; Wilfried Budach
Journal:  Radiat Oncol       Date:  2015-03-28       Impact factor: 3.481

Review 6.  How Can Imaging Help the Radiation Oncologist in Multiple Myeloma Treatment.

Authors:  Liliana Belgioia; Stefano Vagge; Alberto Tagliafico; Renzo Corvò
Journal:  Medicina (Kaunas)       Date:  2020-12-28       Impact factor: 2.430

7.  Single vs. multiple fraction regimens for palliative radiotherapy treatment of multiple myeloma : A prospective randomised study.

Authors:  Milda Rudzianskiene; Arturas Inciura; Rolandas Gerbutavicius; Viktoras Rudzianskas; Andrius Macas; Renata Simoliuniene; Ruta Dambrauskiene; Greta Emilia Kiavialaitis; Elona Juozaityte
Journal:  Strahlenther Onkol       Date:  2017-06-01       Impact factor: 3.621

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.